Publications by authors named "Zehra Arkir"
Article Synopsis
- Adalimumab therapeutic drug monitoring (TDM) was successfully integrated into a national psoriasis service, aiming to improve treatment responses by evaluating serum drug concentrations.
- Out of 229 patients, 74% received TDM, with significant clinical improvement noted in nonresponders who adjusted their medication based on TDM results.
- The study highlights that tailored implementation strategies and regular assessments can help translate biomarker research into practical applications in patient care.
Article Synopsis
- * Data from over 11,000 patients showed that those on infliximab and adalimumab had lower seroprevalence rates for SARS-CoV-2 compared to those on vedolizumab, indicating potential differences in immune response.
- * Higher rates of seropositivity were found in patients with undetectable anti-TNF drug levels, suggesting that the presence of these drugs may hinder the body’s ability to produce antibodies after infection.
Background: Biologics account for a significant cost in inflammatory bowel disease (IBD) management; however, switching from infliximab originator to its biosimilars has enabled cost saving without compromising disease control. The effects on IBD activity and infliximab trough levels of a second switch to another biosimilar are, however, uncertain.
Aims: To assess the effects on disease activity and infliximab trough levels associated with switching from infliximab biosimilar CT-P13 to another biosimilar SB2 and compare outcomes in those switching for the first and second time.
Background: Significant associations between serum golimumab concentrations and favourable outcomes have been observed during both induction and maintenance therapy in ulcerative colitis (UC). However, data regarding optimal therapeutic serum golimumab concentration thresholds are limited.
Aims: To identify optimal serum golimumab concentration thresholds during induction and maintenance treatment with golimumab.
Background: Currently, treatment decisions for people with Crohn disease are based on clinical judgment and trial and error. Consequently, people may continue to receive high drug dosages and experience unnecessary toxicity when it is possible to reduce or discontinue without a detrimental effect on clinical outcomes. Therapeutic drug monitoring (TDM) involves regularly testing blood samples for drug and antibody levels that could help clinicians identify the optimal treatment strategy and pre-empt treatment failure.
View Article and Find Full Text PDFBackground: We aimed to understand the way in which therapeutic drug monitoring (TDM) is used, understood and interpreted for anti-TNF agents in IBD.
Research Design And Methods: We designed an 18-question survey that included 5 TDM-based clinical scenarios, for which the 'most appropriate' responses were based on the BRIDGe groups 'Anti-TNF Optimizer'. This resource combines TDM evidence with expert consensus.